RISE: A Clinical Evaluation of the StarClose™ Vascular Closure System
NCT ID: NCT00736086
Last Updated: 2008-08-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
165 participants
Study Classification
OBSERVATIONAL
Study Start Date
2006-03-31
Study Completion Date
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To evaluate early ambulation in patients who receive the StarClose™ VCS post-percutaneous diagnostic procedure.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To evaluate the StarClose™ VCS in the femoral artery in subjects who are ambulated early post-percutaneous cardiac or peripheral vascular, diagnostic catheterization procedure. The clinical use of vascular closure devices for rapid hemostasis after femoral access was first reported in 1991. 18 participants may be ambulated almost immediately after diagnostic coronary angiography and discharged many hours earlier than currently practiced in most centers utilizing a supine restriction period of 6 hours after diagnostic catheterization.14 After coronary interventions, participant comfort is additionally increased by immediate sheath removal.
This early ambulation study is an evaluation of a clip-based technology, which achieves vascular hemostasis with the use of a novel extravascular Nitinol clip to provide an immediate mechanical closure that does not depend upon the body's clotting system. The procedures will be performed in participants who meet specific entrance criteria.
This early ambulation study is an evaluation of a clip-based technology, which achieves vascular hemostasis with the use of a novel extravascular Nitinol clip to provide an immediate mechanical closure that does not depend upon the body's clotting system. The procedures will be performed in participants who meet specific entrance criteria.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Peripheral Vascular Disease
Cardiovascular Disease
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
femoral artery
post-percutaneous cardiac catheterization
post-percutaneous peripheral vascular catheterization
post-percutaneous diagnostic catheterization
early ambulation
vascular closure
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Subjects who are ambulated early post-percutaneous, cardiac or peripheral vascular, diagnostic catheterization procedures with the use of StarClose® Vascular Closure System in the femoral artery after diagnostic catheterization procedure.
Vessel Closure (StarClose™)
Intervention Type
DEVICE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vessel Closure (StarClose™)
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must be 18-85.
* Subject must be an acceptable candidate for an elective,non-emergent diagnostic procedure performed percutaneously via the common femoral artery through either a 5F or 6F procedural sheath.
* Subject is an acceptable candidate for emergent vascular surgery.
* Subject agrees to follow-up evaluations to assess for complications related to femoral access site.
* If among the 50 ultrasound sub-study Subjects enrolled,Subject agrees to have an ultrasound of femoral artery performed post-procedure during the 30 ± 7 days follow-up visit.
* Subject or legal representative has been informed of the nature of the study and agrees to provisions and has provided written informed consent as approved by the Institutional Review Board of respective clinical site.
Exclusion:
* History of bleeding diathesis or coagulopathy including hemophilia, von Willebrand's disease, and/or a current, known platelet count \<100,000 cells/mm3, or baseline INR \> 1.7.
* Body Mass Index (BMI) ³ 35 kg/m2.
* Presence of significant anemia (Hgb \< 10 g/dL, Hct \< 30%).
* Advanced Subject refusal of blood transfusions, should transfusion become necessary.
* Participation in another trial of an investigational drug or device that has not yet completed follow-up requirements.
* Pregnant or lactating female.
* Clinically severe peripheral vascular disease in the ipsilateral limb, defined as severe claudication (walking \< 100 feet), weak or absent pulses, or lower extremity vascular graft.
* History of ipsilateral femoral arterial puncture within previous three months or history of vascular closure device deployment in ipsilateral femoral artery at any time.
* Subject has unilateral or bilateral lower extremity amputation(s).
* Subject is unable to routinely walk at least 20 feet without assistance.
* Subject has an active systemic or cutaneous infection or inflammation.
* Subject has a pre-existing severe non-cardiac systemic disease or illness with a life expectancy of \< 30 days.
* Subject has already participated in this Study.
* Subject has known allergy to nitinol.
Access Site Exclusion-(\*Evaluated via Limited Femoral Angiogram)
* Pseudoaneurysm or AV fistula present in ipsilateral femoral artery prior to arterial closure.\*
* Puncture distal to the common femoral artery bifurcation or above the inguinal ligament which is typically defined by the inferior border of the inferior epigastric artery on sheath angiogram or the upper third of the femoral head by plain fluoroscopy.\*
* The arterial lumen diameter at the arteriotomy site is \< 5mm by visual estimate.\*
* Angiographic evidence of calcified lesions at the arteriotomy site.\*
* Difficulty inserting the introducer sheath at the start of the catheterization procedure due to vessel scarring or tortuosity, or anterior/posterior wall femoral artery punctures or greater than 2 ipsilateral arterial puncture attempts at the time of the percutaneous procedure.
* Known iliac or femoral stenosis \>50% or previous bypass surgery or stent placement in the vicinity of the puncture site.
* Planned percutaneous procedure (diagnostic or intervention) in ipsilateral femoral artery prior to the 30-day follow-up evaluation.
* Subject has intra-procedural bleeding around the access site.
* Presence or previous use of an intra-aortic balloon pump through the existing arterial puncture site.
Procedural Exclusion:
* Low molecular weight heparin administration within 8 hours of enrollment.
* For cases where anticoagulants are used, ACT level \> 350 seconds at time of enrollment.
* Subject is determined to require treatment that will extend hospitalization (e.g. ---Subject is undergoing CABG surgery or staged PTCA).
* Persistent hypertension (SBP \>180 or DBP \>110 mm Hg) unresponsive to medical -therapy at time of enrollment.
* Placement of an ipsilateral femoral venous sheath during procedure.
* Presence of clinically significant hematoma (\> 6 cm) in ipsilateral femoral artery prior to arterial closure.
* Placement of introducer sheath \< 5F or \> 6F during procedure.
* Subject must be an acceptable candidate for an elective,non-emergent diagnostic procedure performed percutaneously via the common femoral artery through either a 5F or 6F procedural sheath.
* Subject is an acceptable candidate for emergent vascular surgery.
* Subject agrees to follow-up evaluations to assess for complications related to femoral access site.
* If among the 50 ultrasound sub-study Subjects enrolled,Subject agrees to have an ultrasound of femoral artery performed post-procedure during the 30 ± 7 days follow-up visit.
* Subject or legal representative has been informed of the nature of the study and agrees to provisions and has provided written informed consent as approved by the Institutional Review Board of respective clinical site.
Exclusion:
* History of bleeding diathesis or coagulopathy including hemophilia, von Willebrand's disease, and/or a current, known platelet count \<100,000 cells/mm3, or baseline INR \> 1.7.
* Body Mass Index (BMI) ³ 35 kg/m2.
* Presence of significant anemia (Hgb \< 10 g/dL, Hct \< 30%).
* Advanced Subject refusal of blood transfusions, should transfusion become necessary.
* Participation in another trial of an investigational drug or device that has not yet completed follow-up requirements.
* Pregnant or lactating female.
* Clinically severe peripheral vascular disease in the ipsilateral limb, defined as severe claudication (walking \< 100 feet), weak or absent pulses, or lower extremity vascular graft.
* History of ipsilateral femoral arterial puncture within previous three months or history of vascular closure device deployment in ipsilateral femoral artery at any time.
* Subject has unilateral or bilateral lower extremity amputation(s).
* Subject is unable to routinely walk at least 20 feet without assistance.
* Subject has an active systemic or cutaneous infection or inflammation.
* Subject has a pre-existing severe non-cardiac systemic disease or illness with a life expectancy of \< 30 days.
* Subject has already participated in this Study.
* Subject has known allergy to nitinol.
Access Site Exclusion-(\*Evaluated via Limited Femoral Angiogram)
* Pseudoaneurysm or AV fistula present in ipsilateral femoral artery prior to arterial closure.\*
* Puncture distal to the common femoral artery bifurcation or above the inguinal ligament which is typically defined by the inferior border of the inferior epigastric artery on sheath angiogram or the upper third of the femoral head by plain fluoroscopy.\*
* The arterial lumen diameter at the arteriotomy site is \< 5mm by visual estimate.\*
* Angiographic evidence of calcified lesions at the arteriotomy site.\*
* Difficulty inserting the introducer sheath at the start of the catheterization procedure due to vessel scarring or tortuosity, or anterior/posterior wall femoral artery punctures or greater than 2 ipsilateral arterial puncture attempts at the time of the percutaneous procedure.
* Known iliac or femoral stenosis \>50% or previous bypass surgery or stent placement in the vicinity of the puncture site.
* Planned percutaneous procedure (diagnostic or intervention) in ipsilateral femoral artery prior to the 30-day follow-up evaluation.
* Subject has intra-procedural bleeding around the access site.
* Presence or previous use of an intra-aortic balloon pump through the existing arterial puncture site.
Procedural Exclusion:
* Low molecular weight heparin administration within 8 hours of enrollment.
* For cases where anticoagulants are used, ACT level \> 350 seconds at time of enrollment.
* Subject is determined to require treatment that will extend hospitalization (e.g. ---Subject is undergoing CABG surgery or staged PTCA).
* Persistent hypertension (SBP \>180 or DBP \>110 mm Hg) unresponsive to medical -therapy at time of enrollment.
* Placement of an ipsilateral femoral venous sheath during procedure.
* Presence of clinically significant hematoma (\> 6 cm) in ipsilateral femoral artery prior to arterial closure.
* Placement of introducer sheath \< 5F or \> 6F during procedure.
Minimum Eligible Age
18 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott Medical Devices
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abbott Vascular
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William Kussmaul, MD
Role: PRINCIPAL_INVESTIGATOR
Drexel University/Hahnemann
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scripps Memorial Hospital
La Jolla, California, United States
Site Status
Fuqua Heart Center/ Piedmont Hospital
Atlanta, Georgia, United States
Site Status
Heart Care Midwest (OSF/St Francis)
Peoria, Illinois, United States
Site Status
The Care Group LLC (St. Vincent's Hospital)
Indianapolis, Indiana, United States
Site Status
Bay Regional Medical Center
Bay City, Michigan, United States
Site Status
Minneapolis Heart Institute Foundation/Abbott Northwestern Hospital
Minneapolis, Minnesota, United States
Site Status
St. Luke's Hospital
Kansas City, Missouri, United States
Site Status
New York Methodist Hospital
Brooklyn, New York, United States
Site Status
Buffalo Heart group
Buffalo, New York, United States
Site Status
North Ohio Research LTD Elyria Regional Medical
Elyria, Ohio, United States
Site Status
Drexel University College of Medicine Hahnemann
Philadelphia, Pennsylvania, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Krone RJ, Johnson L, Noto T. Five year trends in cardiac catheterization: a report from the Registry of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn. 1996 Sep;39(1):31-5. doi: 10.1002/ccd.1810390102.
Reference Type
BACKGROUND
Waksman R, Scott NA, Ghazzal ZM, Mays R, Frerichs FA, Petersen JY, King SB 3rd. Randomized comparison of flexible versus nonflexible femoral sheaths on patient comfort after angioplasty. Am Heart J. 1996 Jun;131(6):1076-8. doi: 10.1016/s0002-8703(96)90079-4.
Reference Type
BACKGROUND
Bogart DB, Bogart MA, Miller JT, Farrar MW, Barr WK, Montgomery MA. Femoral artery catheterization complications: a study of 503 consecutive patients. Cathet Cardiovasc Diagn. 1995 Jan;34(1):8-13. doi: 10.1002/ccd.1810340304.
Reference Type
BACKGROUND
Christensen B, Lacarella C, Manion R, Bruhn-Ding B, Meyer S, Wilson R. Sandbags do not prevent complications after catheterization. Circulation 90:I-205, 1994.
Reference Type
BACKGROUND
Pracyk JB, Wall TC, Longabaugh JP, Tice FD, Hochrein J, Green C, Cox G, Lee K, Stack RS, Tcheng JE. A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention. Am J Cardiol. 1998 Apr 15;81(8):970-6. doi: 10.1016/s0002-9149(98)00074-5.
Reference Type
BACKGROUND
Resar JR, Prewitt KC, Wolff MR, Blumenthal R, Raqueno JV, Brinker JA. Percutaneous transluminal coronary angioplasty through 6F diagnostic catheters: a feasibility study. Am Heart J. 1993 Jun;125(6):1591-6. doi: 10.1016/0002-8703(93)90745-u.
Reference Type
BACKGROUND
Cragg AH, Nakagawa N, Smith TP, Berbaum KS. Hematoma formation after diagnostic angiography: effect of catheter size. J Vasc Interv Radiol. 1991 May;2(2):231-3. doi: 10.1016/s1051-0443(91)72287-2.
Reference Type
BACKGROUND
Waksman R, King SB 3rd, Douglas JS, Shen Y, Ewing H, Mueller L, Ghazzal ZM, Weintraub WS. Predictors of groin complications after balloon and new-device coronary intervention. Am J Cardiol. 1995 May 1;75(14):886-9. doi: 10.1016/s0002-9149(99)80681-x.
Reference Type
BACKGROUND
Campeau L. Percutaneous radial artery approach for coronary angiography. Cathet Cardiovasc Diagn. 1989 Jan;16(1):3-7. doi: 10.1002/ccd.1810160103.
Reference Type
BACKGROUND
Kiemeneij F, Laarman GJ, Odekerken D, Slagboom T, van der Wieken R. A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the access study. J Am Coll Cardiol. 1997 May;29(6):1269-75. doi: 10.1016/s0735-1097(97)00064-8.
Reference Type
BACKGROUND
Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation. 1998 Oct 20;98(16):1597-603. doi: 10.1161/01.cir.98.16.1597.
Reference Type
BACKGROUND
Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998 Dec 3;339(23):1665-71. doi: 10.1056/NEJM199812033392303.
Reference Type
BACKGROUND
Dick RJ, Popma JJ, Muller DW, Burek KA, Topol EJ. In-hospital costs associated with new percutaneous coronary devices. Am J Cardiol. 1991 Oct 1;68(9):879-85. doi: 10.1016/0002-9149(91)90403-8.
Reference Type
BACKGROUND
Krause PB, Klein LW. Utility of a percutaneous collagen hemostasis device: to plug or not to plug? J Am Coll Cardiol. 1993 Nov 1;22(5):1280-2. doi: 10.1016/0735-1097(93)90530-e. No abstract available.
Reference Type
BACKGROUND
Anderson HV, Bertrand M, Whitworth HB, Sax FL, Willerson JT for the Restore Investigators. Bleeding risk with platelet inhibition using Tirofiban: The Restore Trial. Circulation. 94:I-553, 1996.
Reference Type
BACKGROUND
Lincoff AM, Tcheng JE, Miller DP, Booth JE, Montague EA, Topol EJ. Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3Fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials. Circulation 94:I-375, 1996.
Reference Type
BACKGROUND
Goods CM, Liu MW, Jain SP, Mathur A, Yadav JS, Al-Shalbi KF, Dean LS, Iyer SS, Parks JM, Roubin GS. Low molecular weight heparin versus standard heparin in participants at high risk for stent thrombosis: Clinical outcomes. Circulation 94:I-684, 1996.
Reference Type
BACKGROUND
Ernst S, Kloss R, Schräder R, Kaltenbach M, Sigwart U, Sanborn TA. Immediate sealing of arterial puncture sites after catheterization and PTCA using a vascular hemostasis device with collagen: an international study. Circulation 84:I-272, 1991.
Reference Type
BACKGROUND
Silber S, Dorr R, Muhling H, Konig U. Sheath pulling immediately after PTCA: comparison of two different deployment techniques for the hemostatic puncture closure device: a prospective, randomized study. Cathet Cardiovasc Diagn. 1997 Aug;41(4):378-83. doi: 10.1002/(sici)1097-0304(199708)41:43.0.co;2-2.
Reference Type
BACKGROUND
Silber S. Rapid hemostasis of arterial puncture sites with collagen in patients undergoing diagnostic and interventional cardiac catheterization. Clin Cardiol. 1997 Dec;20(12):981-92. doi: 10.1002/clc.4960201203.
Reference Type
BACKGROUND
Silber S. Hemostasis success rates and local complications with collagen after femoral access for cardiac catheterization: analysis of 6007 published patients. Am Heart J. 1998 Jan;135(1):152-6. doi: 10.1016/s0002-8703(98)70356-4.
Reference Type
BACKGROUND
Hoffer EK, Bloch RD. Percutaneous arterial closure devices. J Vasc Interv Radiol. 2003 Jul;14(7):865-85. doi: 10.1097/01.rvi.0000071086.76348.8e.
Reference Type
BACKGROUND
Duffin DC, Muhlestein JB, Allisson SB, Horne BD, Fowles RE, Sorensen SG, Revenaugh JR, Bair TL, Lappe DL. Femoral arterial puncture management after percutaneous coronary procedures: a comparison of clinical outcomes and patient satisfaction between manual compression and two different vascular closure devices. J Invasive Cardiol. 2001 May;13(5):354-62.
Reference Type
BACKGROUND
Shammas NW, Rajendran VR, Alldredge SG, Witcik WJ, Robken JA, Lewis JR, McKinney D, Hansen CA, Kabel ME, Harris M, Jerin MJ, Bontu PR, Dippel EJ, Labroo A. Randomized comparison of Vasoseal and Angioseal closure devices in patients undergoing coronary angiography and angioplasty. Catheter Cardiovasc Interv. 2002 Apr;55(4):421-5. doi: 10.1002/ccd.10098.
Reference Type
BACKGROUND
Ward SR, Casale P, Raymond R, Kussmaul WG 3rd, Simpfendorfer C. Efficacy and safety of a hemostatic puncture closure device with early ambulation after coronary angiography. Angio-Seal Investigators. Am J Cardiol. 1998 Mar 1;81(5):569-72. doi: 10.1016/s0002-9149(97)00970-3.
Reference Type
BACKGROUND
Kussmaul WG 3rd, Buchbinder M, Whitlow PL, Aker UT, Heuser RR, King SB, Kent KM, Leon MB, Kolansky DM, Sandza JG Jr. Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: results of a randomized trial of a novel hemostatic device. J Am Coll Cardiol. 1995 Jun;25(7):1685-92. doi: 10.1016/0735-1097(95)00101-9.
Reference Type
BACKGROUND
Kapadia SR, Raymond R, Knopf W, Jenkins S, Chapekis A, Ansel G, Rothbaum D, Kussmaul W, Teirstein P, Reisman M, Casale P, Oster L, Simpfendorfer C. The 6Fr Angio-Seal arterial closure device: results from a multimember prospective registry. Am J Cardiol. 2001 Mar 15;87(6):789-91, A8. doi: 10.1016/s0002-9149(00)01507-1.
Reference Type
BACKGROUND
Burke MN, Hermiller J, Jaff MR. StarClose vascular closure system (VCS) is safe and effective in patients who ambulate early following successful femoral artery access closure--results from the RISE clinical trial. Catheter Cardiovasc Interv. 2012 Jul 1;80(1):45-52. doi: 10.1002/ccd.23176. Epub 2011 Dec 8.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AVD-640-0057
Identifier Type: -
Identifier Source: org_study_id